Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience.

Abstract

PURPOSE:

The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis.

METHODS:

One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 ± 14.34 days before the surgery, and it was continued for 4.39 ± 3.11 months postoperatively. A total of 1.7 µg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 ± 51.56 months.

RESULTS:

Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively.

CONCLUSION:

Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.

• Authors: Kagan Karabulut, G Selcuk Ozbalci, Tugrul Kesicioglu, Ismail Alper Tarim, Gokhan Lap, Ayfer Kamali Polat, Ilhan Karabıcak, Kenan Erzurumlu
• Journal: Annals of surgical treatment and research (Ann Surg Treat Res) Vol. 87 Issue 2 Pg. 61-5 (Aug 2014) ISSN: 2288-6575 [Print] Korea (South)
• PMID: 25114884 (Publication Type: Journal Article)